Effects of cyclophosphamide on the development of malignancy and on long‐term survival of patients with rheumatoid arthritis a 20‐year followup study

1995314 citationsJournal Article

Authors

The risk of malignancy, particularly bladder cancer, in RA patients treated with oral CYC continues even 17 years after discontinuation of the drug.

Good health and well-being

Published in: Arthritis & Rheumatism

Volume 38, Issue 8, pp. 1120-1127

Field-Weighted Citation Impact: 8.66